Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Purchases 86,432 Shares of Company Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker bought 86,432 shares of the stock in a transaction dated Thursday, November 5th. The stock was bought at an average price of $98.51 per share, with a total value of $8,514,416.32. Following the purchase, the director owned 20,424,859 shares of the company’s stock, valued at approximately $2,012,052,860.09. This represents a 0.42% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Wednesday, November 4th, Bros. Advisors Lp Baker bought 160,658 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $98.51 per share, for a total transaction of $15,826,419.58.
• On Monday, September 28th, Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock. The shares were bought at an average cost of $72.57 per share, with a total value of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 418,323 shares of Kodiak Sciences stock. The shares were purchased at an average price of $83.58 per share, for a total transaction of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker bought 33,726 shares of Kodiak Sciences stock. The stock was acquired at an average cost of $85.05 per share, with a total value of $2,868,396.30.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 681,866 shares of Kodiak Sciences stock. The stock was acquired at an average price of $88.77 per share, with a total value of $60,529,244.82.

Kodiak Sciences Stock Performance

Shares of NASDAQ:KOD opened at $99.30 on Friday. The firm has a market cap of $6.24 billion, a P/E ratio of -23.70 and a beta of 2.02. The business’s 50 day simple moving average is $69.56 and its two-hundred day simple moving average is $43.69. Kodiak Sciences Inc. has a 52-week low of $15.83 and a 52-week high of $104.00.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). On average, equities analysts forecast that Kodiak Sciences Inc. will post -3.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kodiak Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Kodiak Sciences in the second quarter worth about $161,113,000. Jupiter Topco LLC bought a new stake in Kodiak Sciences during the second quarter worth about $59,507,000. ICONIQ Capital LLC purchased a new stake in shares of Kodiak Sciences during the 2nd quarter worth approximately $49,345,000. Bank of America Corp DE purchased a new position in shares of Kodiak Sciences during the second quarter valued at approximately $14,949,000. Finally, Boone Capital Management LLC purchased a new stake in Kodiak Sciences in the 2nd quarter valued at about $14,727,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Kodiak Sciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, October 4th. Lifesci Capital raised their price objective on Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Weiss Ratings cut shares of Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. Jefferies Financial Group reiterated a “buy” rating and set a $112.00 target price on shares of Kodiak Sciences in a report on Monday, September 28th. Finally, The Goldman Sachs Group initiated coverage on shares of Kodiak Sciences in a research note on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target for the company. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.71.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.